繁體版 簡體版
 
SciVision Biotech Inc. attended the listing ceremony held by Taiwan Stock Exchange Corporation (TWSE) on November 12th in 2013. (Stock symbol: 1786)
   
The only company mass produces Hyaluronic Acid by fermentation biotechnology in Taiwan.

SciVision Biotech Inc. was established by a professional team with master’s and doctoral degrees in the hinterland of Kaohsiung Harbor in 2001. SciVision Biotech Inc. manufactures Hyaluronic acid products by using own-developed Cross-linked Hyaluronic Acid Platform (CHAP), and breaks the bottleneck of modern technology, making the characteristics of Hyaluronic acid products be precisely controllable, and can be widely used in the production of cross-linked Hyaluronic acid products with different states and physical properties. The technology of Cross-linked Hyaluronic Acid Platform (CHAP) established the leading position of SciVision Biotech Inc. in the field of medical grade Hyaluronic acid products.

Dermal Implant
   
Absorbable Adhesion Barrier
 
 
Synovial Fluid Supplement
 
   
Intravesical Instillation
 
The Leading Technology of Hyaluronic Acid
 
more